All In Biotech

Drug Trial Radar · NCT01386294

Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection

A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection

Last checked: Nov 19, 2026Latest source record: Apr 17, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,059 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,059

Actual

Start

Oct 2011

Primary completion

Aug 2014

Study completion Aug 2014

Sponsor

Lead sponsor
CONRADAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Follow-on African Consortium for Tenofovir Studies (FACTS); United States Agency for International Development (USAID)
First posted
Jul 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety and effectiveness of intravaginal 1% tenofovir gel in preventing Human Immunodeficiency Virus (HIV-1) infection and Herpes Simplex Virus (HSV-2) infection in sexually active women.

Conditions

  • HIV Prevention

Interventions

  • Tenofovir gelDrug

    Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.

  • Universal placebo gelDrug

    The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EffectivenessTime frame: 30 months
  2. SafetyTime frame: 30 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Desmond Tutu HIV Centre / University of Cape Town

    Cape Town, South Africa

  • Perinatal HIV Research Unit / University of the Witwatersrand

    Diepkloof, South Africa

  • Wits Reproductive Health and HIV Institute / University of the Witwatersrand

    Hillbrow, South Africa

  • Qhakaza Mbokodo Research Clinic

    Ladysmith, South Africa

  • Medunsa Clinical Research Unit / Ga-Ra

    Pretoria, South Africa

  • The Aurum Institute (Rustenburg)

    Rustenburg, South Africa

  • Setshaba Research Centre

    Soshanguve, South Africa

  • The Aurum Institute, Tembisa Hospital

    Tembisa, South Africa

  • MatCH Edendale Research Center

    Pietermaritzburg, KwaZulu-Natal, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.